159 results about "Hypersensitivity Diseases" patented technology

To provide a pharmaceutical agent that has STAT6 inhibitory activity and is effective for the treatment of allergic diseases and inflammatory diseases such as atopic dermatitis.SOLUTION: A pharmaceutical agent contains, as an active ingredient, a compound represented by the general formula (I) in the figure or a pharmaceutically acceptable salt thereof, which has STAT6 inhibitory activity.SELECTED DRAWING: None

The invention discloses an application of a breast milk-derived plant lactobacillus in improving allergic diseases and regulating intestinal flora, and belongs to the technical field of microorganisms. The plant lactobacillus GDMCC No: 63060 disclosed by the invention is obtained by being separated from breast milk. The strain provided by the invention has excellent gastrointestinal fluid tolerance, mucin adhesion and antibiotic sensitivity, can inhibit various pathogenic bacteria, can generate indole derivatives, effectively inhibits eczema mouse dermatitis symptoms, inhibits Th2 type immunoreaction hyperpolarization, and induces regulatory T cells. Therefore, the lactobacillus plantarum FN029 has a huge application prospect in preparation of products for inhibiting enteropathogenic bacteria, improving allergic diseases, regulating intestinal flora or promoting digestion function.

The invention provides a full-human anti-Der p1 full-molecule IgG antibody and application thereof, and relates to the field of biological pharmacy. The full-human anti-Der p1 full-molecule IgG antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the antigen complementary determining regions CDR of the light chain variable region are respectively as shown in SEQ ID NO.15, SEQ ID NO.16 and SEQ ID NO.17; the amino acid sequences of the antigen complementary determining region CDR of the heavy chain variable region are respectively shown as SEQ ID NO. 18, SEQ ID NO. 19 and SEQ ID NO. 20. The full-human anti-Der p1 full-molecule IgG antibody provides high specificity, high affinity, low immunogenicity and potential immunomodulatory function through the specific CDR design, and can provide a new treatment and diagnosis means for allergic diseases caused by dust mites.

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

Provided are a recombinant cat allergen, a pharmaceutical composition therefor, a preparation method therefor, and a use thereof. Compared with naturally extracted allergen products, the recombinant cat allergen has multiple advantages in desensitization immunotherapy and allergen diagnosis for cat allergic diseases. For example, high purity and high uniformity are achieved; a pure protein / peptide having specified properties and quality is defined; the allergenicity, immunogenicity, and tolerability of the allergen are predetermined; production is performed according to GMP standards; the production of a specified quantity and concentration in a reproducible manner is enabled; product standardization and quality controllability are achieved; regulatory requirements for modern pharmaceuticals and vaccines are met; and when used for diagnosis, the allergen can identify allergen molecules that truly cause allergic reactions and reveal cross-reactivity, and when used for treatment, the allergen enables targeted allergen immunotherapy for a patient, avoiding the influence of non-allergenic substances in an extract, improving the safety, and facilitating precise diagnosis, precise administration, etc.

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium bifidum NKUFB3-12 and a composition thereof in preparation of products for relieving allergic diseases and / or regulating intestinal flora caused by allergy. The preservation number of the bifidobacterium bifidum NKUFB3-12 is GDMCC (China General Microbiological Culture Collection Center) No. 64013. The bifidobacterium bifidum NKUFB3-12 disclosed by the invention has excellent functional characteristics of relieving allergic diseases and regulating allergic intestinal flora, and also has excellent probiotic characteristics of acid resistance, cholate resistance and oxidation resistance, and the strain is safe and has no adverse side effect after being taken. The invention provides a composition. The composition comprises bifidobacterium bifidum NKUFB3-12 and 2 '-fucosyllactose (2'-FL), and the NKUFB3-12 is compounded with the 2 '-FL to show an effective inhibition effect on the imbalance of allergic immune response.

The invention relates to lactobacillus paracasei SINEFREE with anti-inflammatory and anti-allergy effects and application of the lactobacillus paracasei SINEFREE. The lactobacillus paracasei SINEFREE is classified and named as lactobacillus paracasei, and the preservation number of the lactobacillus paracasei SINEFREE is CGMCC (China General Microbiological Culture Collection Center) No.31279. The lactobacillus paracasei SINEFREE is lactobacillus paracasei. The strain plays a remarkable role in regulating and improving the aspects of reducing the level of inflammatory cytokines in a mouse body, regulating the level of serum-related inflammatory antibodies, reducing the nose wiping frequency of an allergic mouse and relieving lung tissue injury. Therefore, the lactobacillus paracasei strain can be used for preparing a product with anti-inflammatory and anti-allergy effects, and provides a coping strategy and a reference basis for prevention and treatment of related allergic diseases.

Aspects of the application provide anti-IL-13 antibodies and methods of using the same in treating IL-13-mediated diseases (e.g., allergic disease or other inflammatory diseases).

The present invention relates to interleukin-2 (IL-2) variants for use in the prevention or treatment of immune disorders, including but not limited to allergic diseases, autoimmune diseases, chronic or acute inflammation, and infectious diseases; graft versus host disease; transplant rejection and cancer. The present invention also relates to the use of said IL-2 variant for screening for anti-IL-2 antibodies having T effector promoting cell or T regulatory promoting cell activity.

The invention relates to a preparation method of a CpG ODN nano immune complex, which comprises the following steps: (1) uniformly mixing a protamine solution with a certain concentration and a CpG motif-containing oligodeoxynucleotide CpG ODN aqueous solution with a certain concentration according to a certain ratio, and carrying out electrostatic compounding assembly at room temperature to form a suspension; and (2) applying energy to the suspension to disperse / homogenize uniformly to form the suspension of the nano-composite. The nano-composite prepared by the method disclosed by the invention is controllable in particle size and controllable in surface charge. The nano particles formed under the preparation condition of an optimized proportion are uniformly dispersed, good in stability, good in resolubility after freezing, and good in long-term storage stability. The preparation method provided by the invention is simple, does not involve toxic and harmful chemical substances, and is suitable for amplification. Compared with the prior art, the preparation method provided by the invention can obviously improve the effective concentration of the effective active substance CpG ODN in the nano immune complex. The invention also relates to the nano immune complex prepared by the method and application thereof. Cell and animal experiments prove that the nano immune complex prepared by the method has good immunostimulatory activity, can stimulate the maturation of related immune cells and induce the secretion of related cytokines, can be independently used as an immunomodulator, and can also be used as an immunologic adjuvant to be combined with various antigens to be used as a vaccine preparation as a whole. The nano immune complex has good application prospects in the fields of inducing and activating immune cells to mature, releasing cytokines, resisting allergic diseases, preventing and treating microbial infectious diseases, vaccine adjuvants, resisting tumor immunotherapy and resisting Alzheimer's disease.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

The invention provides a recombinant artemisia argyi pollen type III allergen protein Art v3 and a coding gene and an expression and purification method thereof, the amino acid sequence of the protein is as shown in SEQ ID NO: 2, the coding nucleotide sequence is as shown in SEQ ID NO: 1, and the recombinant artemisia argyi pollen type III allergen protein Art v3 can be used for preparing drugs for treating artemisia pollen allergic diseases or diagnostic reagents for detecting artemisia pollen allergens.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

Antibody drugs have been proposed to treat allergic diseases, but the route of administration is limited to intravenous route, which is inconvenient for patients. In addition, novel agents that inhibit kinases such as NIK are always needed to develop effective drugs and other products to treat allergic diseases. At least one compound selected from mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) having a xanthone structure can improve allergic diseases and can be effective when taken orally.

Disclosed is a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

Inhibitory nucleic acid molecules are provided as well as methods of use thereof. Specifically, the disclose provides an Inhibin BetaA (inhba) inhibitory nucleic acid molecule, which is an antisense oligonucleotide, siRNA, or shRNA. Further disclosed are sequences that are targeted by the inhba inhibitory nucleic acid molecule; and methods of treating a disease or disorder in a subject comprising administering an inhba inhibitory nucleic acid molecule to the subject, wherein the disease or disorder is selected from the group consisting of cancers, autoimmune diseases, fibrotic disorders, blood disorders, allergies and allergic diseases, heart failure, neurodegenerative diseases, cachexia and inflammatory diseases.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises five structural domains, namely an antigen specific binding domain, a hinge domain, a transmembrane domain, a co-stimulation domain and a CD3 zeta signal transduction domain, the antigen specific binding structural domain can be specifically bound with an antigen comprising immune globulin IgE; the invention also provides an application of the immunoglobulin E in preparation of a long-acting medicine for treating IgE-mediated allergic diseases. Compared with the prior art, the application has the advantages that the anti-IgE monoclonal antibody is combined with a CAR-T technology, IgE protein generated in a targeting manner is converted into B cells generating IgE in a targeting manner, the killing effect of IgE CAR-T on mIgE + B cells is proved in in-vitro and in-vivo experiments, and the problems that the half-life period of a monoclonal antibody drug is short, and high-frequency medication is needed are solved. In addition, the invention also provides a scheme for carrying out an in-vivo experiment by utilizing the humanized mouse model, and successfully verifies the treatment effect of the CAR-T.

The invention relates to a gene therapy vector nucleic acid construct for allergic diseases and a use method of the gene therapy vector nucleic acid construct. In particular to an expression cassette, the expression cassette comprises the following elements: a promoter, an optional first signal peptide coding sequence, a heavy chain coding sequence of an anti-IgE antibody, an optional linker sequence, an optional second signal peptide coding sequence and a light chain coding sequence of the anti-IgE antibody, and the invention also provides an adeno-associated virus vector containing the expression cassette. The gene expression framework of the adeno-associated virus vector can realize high-level expression of a target gene, and can be used for treating allergic diseases such as allergic asthma and chronic spontaneous urticaria.

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.

The present invention relates to a DcR3 variant, DNA encoding the DcR3 variant, a vector containing the DNA, a transformant obtained by introducing the vector, a method for producing a variant using the transformant, and a prophylactic or therapeutic agent for an autoimmune disease, an inflammatory disease or an allergic disease comprising the variant as an active ingredient. The present invention relates to a DcR3 variant having binding activity (preferably neutralizing activity) against a ligand of DcR3 while showing reduced production of aggregates and / or improved in vivo kinetics compared to wild-type DcR3 when prepared with a mammalian-derived cell as a host, and provides a DcR3 variant comprising a portion of DcR3 and a portion of a TNF superfamily molecule.

The invention discloses a multilayer nanofiber oral paste loaded with an allergen-immunologic adjuvant composition as well as a preparation method and application of the multilayer nanofiber oral paste. The multilayer nanofiber oral paste has an adhesion function. The multilayer nanofiber oral paste is prepared by adopting a continuous electrostatic spinning technology, the adhesion layer is prepared from a polymer material, and the backing layer is prepared from a hydrophobic polymer material. The invention relates to an allergen-immunologic adjuvant composition, and the allergen-immunologic adjuvant composition or a composition nanoparticle is loaded by an adhesive layer. The multi-layer nanofiber oral paste is applied to an oral mucosa area of a patient within a treatment course, so that long-acting release of allergens is realized. After the multi-layer nanofiber oral paste is repeatedly used by a patient, the prevention or treatment of allergic diseases (allergic diseases) can be realized.

The present disclosure relates to an ester derivative prodrug of inotodiol and use thereof. The prodrug not only has increased solubility with respect to an inorganic solvent and an organic solvent, but also has improved stability, and thus can be used in the treatment of various inflammatory diseases, including inflammatory diseases or allergic diseases.

The invention relates to the technical field of medical data processing, and discloses an anaphylactic disease inquiry auxiliary system and method based on digital mobile medical treatment, and the system comprises a digital mobile medical treatment module, an environment monitoring module, a prediction module, a correction module, and a risk calculation module. Wherein the digital mobile medical module is used for acquiring an allergy history of a user, user positioning and an allergy case of an area where the user is located; the environment monitoring module is used for collecting the concentration and the environment factor of each allergen in the area where the user is located; the prediction module is used for predicting the concentration of each allergen in the area where the user is located; the correction module is used for correcting the concentration predicted value of each allergen; the risk calculation module is used for performing allergy early warning on the user; by integrating multiple advanced technologies and methods, the accuracy and timeliness of allergy early warning are improved, and the allergy management ability and life quality of the user are improved.

The present invention provides an isolated antibody or antibody derivative that specifically binds to equine interleukin-5 (eqIL-5), comprising at least one member selected from the group consisting of equine light chain constant, equine heavy chain constant, and fragments thereof. Additionally, provided are isolated nucleic acid molecules comprising nucleic acid sequences encoding the isolated antibody or antibody derivative, vectors comprising the respective nucleic acid sequences, and host cells comprising the isolated nucleic acid molecule. The present invention also provides pharmaceutical compositions comprising the isolated antibody or antibody derivative and a pharmaceutically acceptable excipient. Furthermore, provided are uses of the isolated antibody or antibody derivative or pharmaceutical composition as a medicine, particularly for treating allergic conditions in horses. The present invention also relates to in vitro methods for diagnosing allergic conditions in horses, as well as methods for producing the isolated antibody or antibody derivative.

1. The name of the design product: bioelectromagnetic physical therapy instrument. 2. The use of the design product: the design product is used for the auxiliary treatment of allergic diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The present invention relates to treatment and prevention of allergic diseases and, specifically, to an allergic disease immunomodulation method, which suppresses SIRT7 of nasal cavity epithelial cells to inhibit allergy mediators. The present invention suppresses SIRT7 of nasal cavity epithelial cells to inhibit the secretion of epithelial cell cytokines (TSLP), which recognize allergens to attract immune cells that induce an immune response, so that high-level processes of allergic reactions are blocked, and thus allergic diseases can be fundamentally treated and prevented.

The present invention relates to compounds of formula (I) with STAT6 inhibitory activity for use in methods of treatment of inflammatory or allergic diseases, such as e.g. atopic dermatitis.